RxDoctor Payments Data

Robert Mathews, MD

Nephrology · Northfield, NJNPI 1902060221

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,054 of the $6,574 with a category attached, or 76.9%. Bayer accounts for 84.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $5,364 and has fallen 88.6% since, to $611 in 2025.

$6,574in general payments, 2019–2025

Across 61 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$6K
  • Bard Peripheral Vascular, Inc.$159
  • Fresenius USA Marketing, Inc.$149
  • AstraZeneca$125
  • Neurocrine Biosciences, Inc.$115
  • Travere Therapeutics, Inc.$111
  • plus $360 from 9 others

What the payments were for

  • Speaking & faculty fees$5,05477%
  • Food & beverage$1,51323%
  • Education$70%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,574 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$398,052
Medicare patients
773
Services billed
3,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol177$208,643
JardianceEmpagliflozin143$163,849
KerendiaFinerenone52$94,026
LokelmaSodium Zirconium Cyclosilicate53$40,248
VeltassaPatiromer Calcium Sorbitex24$33,879
JanuviaSitagliptin Phosphate29$31,953
Cinacalcet Hcl42$19,878
AranespDarbepoetin Alfa In Polysorbat11$18,879
MyrbetriqMirabegron11$14,450
Irbesartan438$12,290
Clonidine33$5,333
Carvedilol329$3,612
Torsemide197$3,190
Sevelamer Carbonate17$3,050
Hydralazine Hcl106$3,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$125$248,892230 claims
Boehringer IngelheimJardiance$31$163,849143 claims
BayerKerendia$5,554$94,02652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Northfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →